OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Targeting KDM2/7 histone demethylases could protect against OA	427
Synthetic Wnt agonists rapidly rebuild bone in vivo	344
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	292
Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	266
Annexin A1 could help prevent periprosthetic bone loss	216
Shifting the SLE management paradigm: challenges and implications	211
Targeted NOD2 sequencing uncovers JIA misdiagnosis	210
Osteoarthritis risk factors differ between sexes	204
aPL target links coagulation and autoimmunity	189
Moving towards a molecular categorization of autoimmune disease	185
Tapering csDMARDs leads to more RA flares	162
LACC1-associated JIA linked to autophagy defects in macrophages	160
B cell X-chromosome inactivation is faulty in SLE	157
Polygenic risk scores outperform other tests in AS	156
The emergence of SLE-causing UNC93B1 variants in 2024	148
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	134
Abatacept for myositis	131
SARS-CoV-2 vaccine safe for young patients	125
Stromal cells implicated in RA genetic risk	123
Imaging for prediction of RA development	121
Precision medicine: the precision gap in rheumatic disease	113
Autoimmune disease increases CVD risk	111
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	94
Targeting senescence in OA	91
Immune cartography of macrophage activation syndrome in the COVID-19 era	85

Knee OA progression risk with steroids or HA	84
Are DNA–HLA class II interactions the missing link in SLE?	84
No benefit from adding MTX to ustekinumab	83
Bimekizumab effective across the axSpA spectrum	83
Iron uptake is a therapeutic target in SLE	82
Inflammatory arthritis affects men’s fertility	73
Belimumab an option for Black patients with SLE	73
Response to inflammation differs in gut and joint Treg cells	72
Discontinuing methotrexate to enhance vaccine response	72
Optimizing methotrexate withdrawal during COVID vaccination	69
New treatments for amyloidosis	69
Critical appraisal of serum urate targets in the management of gout	68
New OA risk factors and drug targets revealed	67
Cutaneous bacteria promote autoimmunity in mice	65
Mitophagy as a link between ECM stiffness and chondrocyte senescence	65
Low-dose rituximab can go even lower	65
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	64
Engineering approaches for RNA-based and cell-based osteoarthritis therapies	63
GCA management guidelines — vive la différence?	63
Pre-exposure prophylaxis reduces risk of COVID-19	63
Helicobacter pylori-induced citrullination linked to RA exacerbation	62
Advancing equity in genomic medicine for rheumatology	56
CAR T cells induce remission in a patient with refractory SLE	55
FABP4 exacerbates RA	54
HLA autoimmunity risk alleles influence T cell receptor sequences	53
Rheumatic diseases on the rise	50